{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:11:54Z","timestamp":1790417514695,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jphs.2016.06.004","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T18:09:17Z","timestamp":1467396557000},"page":"198-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice"],"prefix":"10.1016","volume":"131","author":[{"given":"Atsuo","family":"Tahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yokono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2016.06.004_bib1","first-page":"20","article-title":"Diabetes update","volume":"38","author":"Dwarakanathan","year":"2006","journal-title":"J\u00a0Insur Med"},{"key":"10.1016\/j.jphs.2016.06.004_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS20060150","article-title":"Diet, obesity and diabetes: a current update","volume":"112","author":"Walker","year":"2007","journal-title":"Clin Sci"},{"key":"10.1016\/j.jphs.2016.06.004_bib3","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jphs.2016.06.004_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc08-9016","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2016.06.004_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabet"},{"key":"10.1016\/j.jphs.2016.06.004_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.jphs.2016.06.004_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jphs.2016.06.004_bib8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"11","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jphs.2016.06.004_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jphs.2016.06.004_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects","volume":"130","author":"Tahara","year":"2016","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2016.06.004_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in\u00a0vitro and in\u00a0vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.jphs.2016.06.004_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2016.06.004_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.112.191593","article-title":"Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice","volume":"341","author":"Suzuki","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jphs.2016.06.004_bib14","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2016.06.004_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1124\/jpet.113.203869","article-title":"Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats","volume":"345","author":"Kojima","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jphs.2016.06.004_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2011.01.015","article-title":"Effects of antidiabetic drugs in high-fat diet and streptozotocin\u2013nicotinamide-induced type 2 diabetic mice","volume":"655","author":"Tahara","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2016.06.004_bib17","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2016.06.004_bib18","doi-asserted-by":"crossref","first-page":"e54615","DOI":"10.1371\/journal.pone.0054615","article-title":"Association between serum leptin concentrations and insulin resistance: a population-based study from China","volume":"8","author":"Zuo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2016.06.004_bib19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2016.06.004_bib20","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/01.ATV.20.6.1595","article-title":"Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients","volume":"20","author":"Hotta","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jphs.2016.06.004_bib21","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1210\/en.2013-1191","article-title":"Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice","volume":"154","author":"Camporez","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.jphs.2016.06.004_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cca.2012.12.007","article-title":"Role of leptin and adiponectin in insulin resistance","volume":"417","author":"Yadav","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jphs.2016.06.004_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2016.06.004_bib24","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2016.06.004_bib25","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.295.14.1707","article-title":"Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications","volume":"295","author":"Brownlee","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jphs.2016.06.004_bib26","first-page":"98","article-title":"Control of post-prandial hyperglycemia\u2013an essential part of good diabetes treatment and prevention of cardiovascular complications","volume":"12","author":"Hanefeld","year":"2002","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jphs.2016.06.004_bib27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1463-1326.2009.01160.x","article-title":"Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature","volume":"12","author":"Nalysnyk","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jphs.2016.06.004_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diabres.2010.05.004","article-title":"Correlation between glucose fluctuations and carotid intima-media thickness in type 2 diabetes","volume":"90","author":"Chen","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jphs.2016.06.004_bib29","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2337\/dc12-0199","article-title":"Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition","volume":"35","author":"Rizzo","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316300743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316300743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T20:54:23Z","timestamp":1536612863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861316300743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1347861316300743"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2016.06.004","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2016.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}